Pharmacotherapy for Nervous System Disorders. Department of Pharmacology Medical Faculty Lambung Mangkurat University

Similar documents
Sedative H ypnotic D rugs

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

Introduction. 1 person in 20 will have an epileptic seizure at some time in their life

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Drugs used in Parkinsonism

ADVANCES IN MIGRAINE MANAGEMENT

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Anticonvulsants Antiseizure

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in

Antidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych

Strategies in Migraine Care

SEIZURES PHARMACOLOGY. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Faculty of dentistry Second year CND Course CNS Drugs Dr. Ali Awadallah

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Anxiety Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM

Types of epilepsy. 1)Generalized type: seizure activity involve the whole brain, it is divided into:

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

Anxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Anti-epileptic Drugs

Index. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type.

Anti-Depressant Medications

Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins

Buspirone Carbamazepine Diazepam Disulfiram Ethosuximide Flumazeil Gabapentin Lamotrigine

DRUGS THAT ACT IN THE CNS

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)

DRUGS THAT ACT IN THE CNS

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.

ZONISAMIDE THERAPEUTICS. Brands * Zonegran. Generic? Not in US. If It Doesn t Work * Class Antiepileptic drug (AED), structurally a sulfonamide

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Disclosure. Learning Objectives

Management of headache

Faculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest.

Basics of Pharmacology

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

Affective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

Neurostorm: Modern understanding and nomenclature. Mitch Stanek RN, CBIS Charge Nurse/Infection Preventionist On With Life

How do we treat migraine? New SIGN Guidelines

How could I be having migraine when I don't have a headache?

ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา

I. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs)

Package leaflet: Information for the user. Sumatriptan Amneal 100 mg tablets. sumatriptan

First a caution. Processes we might NOT try to treat with medications. Processes we might try to treat. Main drug categories.

Lecture 5 Skeletal muscle relaxants. Pharmacologic management of parkinsonism and other movement disorders.

Chronic Daily Headaches

Drugs, The Brain, and Behavior

improving the patient s quality of life.

PHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS

Drugs, Sleep & Wakefulness. Brian Koo Reena Mehra MD MS Kingman Strohl MD

11/10/16. Neurotransmitters and their Receptors. Professor Abercrombie, Chapter 6, Neuroscience, 4 th ed, D. Purves et el.

Short Clinical Guidelines: Headache, Key Points for Diagnosis and Treatment

Introduction to Drug Treatment

Core Safety Profile. Pharmaceutical form(s)/strength: Tablets and Oral lyophilisates (wafers) 5 and 10 mg NL/H/PSUR/0002/001 Date of FAR:

Drugs Affecting the Central Nervous System

Antiepileptic agents

Maxalt. Maxalt / Maxalt-MLT (rizatriptan) Description. Section: Prescription Drugs Effective Date: April 1, 2016

9.98 Neuropharmacology January (IAP) 2009

1. Foods containing tyramine should not be eaten by patients taking: a. Fluvoxamine b. Imipramine c. Maprotiline d. Nefazodone e.

3. Atypical antidepressants

Antidepressants and Sedatives. David G. Standaert, M.D., Ph.D. Massachusetts General Hospital Harvard Medical School

Classes of Neurotransmitters. Neurotransmitters

M0BCore Safety Profile. Pharmaceutical form(s)/strength: ordispersible tablet SE/H/PSUR/0022/002 Date of FAR:

Chapter 15. Seizures. Learning Objectives. Learning Objectives 9/11/2012

Epilepsy Medications: The Basics

TOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER)

Objectives. Amanda Diamond, MD

Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM

Review of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP

Chapter 4. Psychopharmacology. Copyright Allyn & Bacon 2004

Update on Diagnosis and Management of Migraines

Prof dr Aleksandar Raskovic DIRECT VASODILATORS

Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs

Faculty. Joseph Friedman, MD

DOPAMINE RECEPTOR AGONISTS. Remove OHs. N-Methyl. Subst. Beta-OH. Subst. Alpha-Me. Subst

Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents

Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.

First a caution. Processes we might NOT try to treat with medications. Processes we might try to treat. Main drug categories.

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.

metabolism inhibition, this approach causes other adverse effects. The dosage of L-dopa can be brought down further by co-medication of dopamine

Antidepressant Pharmacology An Overview

Unit VIII Problem 7 Pharmacology: Principles of Management of Seizure Disorders

Parkinson s Disease. Sirilak yimcharoen

Neuro Basics SLO Practice (online) Page 1 of 5

10th Medicine Review Course st July Prakash Kumar

Anxiolytic and Hypnotic drugs

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

Chapter 161 Antipsychotics

Evaluation and Management of Parkinson s Disease in the Older Patient

Margo J Nell Dept Pharmacology

Movement Disorders: A Brief Overview

Chapter 24 Antiseizures

SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)

Study Guide Unit 3 Psych 2022, Fall 2003

Tranquilizers & Sedative-Hypnotics

Ganglionic Blockers. Ganglion- blocking agents competitively block the action of

A. Incorrect! Seizures are not typically linked to alcohol use. B. Incorrect! Epilepsy is a seizure that is commonly associated with convulsions.

Neurodegenerative diseases

AUTACOIDS. Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine, The University of Jordan April, 2014

Seizure medications An overview

Transcription:

Pharmacotherapy for Nervous System Disorders M. Bakhriansyah,, H., dr., M.Kes, M.Med.Ed Department of Pharmacology Medical Faculty Lambung Mangkurat University

Learning outcomes At the end of this course, students should be able to: 1. To explain mechanism of action of drugs used in nervous system disorders treatments. 2. Choose the appropriate medications for status epilepticus, parkinson disease, and cephalgia treatments 3. Explain the chosen medications regarding patients condition. 4. Explain the protocol of therapy of nervous system disorders

Status Epilepticus SE : Continues seizures occuring 30 minutes (epilepsi foundation) More than 30 minutes of continues seizures activity or 2 or more sequential seizures without full recovery of consciousness between seizures (Dodson, 1993).

Systemic and primary brain changes related to morbidity and mortality rates Decreasing GABA inhibition. Increasing blood pressure (early stage) decreasing Acidosis (+) Pulmonary edema Hyperthermia Mild leukocytosis GABAergic mechanism fails

Goal of therapy: to treat the epilepsy and to minimalise the side effects Principal therapy: Monotherapy is better than polypharmacy Dosage is increased until the therapeutic effect or toxicity effect are met. Polypharmacy is introduced when monotherapy does not work Avoiding the sudden withdrawal

Treatment flowchart for status epilepticus

Medications Fenitoin Karbamazepin Lamotrigin Na Glutamate STATUS EPILEPTICUS GABA Ca Barbiturat Benzodiazepin Asam valproat Gabapentin Fenitoin Karbamazepin Asam valproat Etosuksimid

Karbamazepin Stabilize neural membrane by decreasing Na, Ca and K flows through it. avoid to be given with MAO inhibitor consecutively Fenitoin Difenilhidantoin derivate Mechanism of actions are similar to Karbamazepin Could be given orally, intra venous and intra muscular

Valproic Acid Increasing GABA transmission Sedation effect is minimal Etosuksimid Mechanism of action is unknown Probably by inhibiting Ca channel

Phenobarbital Stimulating GABA receptor SE: sedation, nistagmus,, ataxia and allergy Inducing enzym P450 Primidon Mechanism of actions are unknown Its active metabolit has long half life

Gabapentin GABA agonist Adjuvant therapy Lamotrigin Stabilizing neuron and affecting glutamate release Adjuvant therapy SE: rash (prominent)

Klonazepam Stimulating GABA receptor Felbamat Stimulating GABA receptor and inhibiting NMDA receptor Used un-frequently

Parkinson disease A progressive neurodegenerative disorder associated with loss of dopaminergic nigrostriatal neurons. Distinctive features: Resting tremor, rigidity, bradikinetia,, and postural instability

Principle therapy To facilitate action of dopaminergic To suppress action of cholinergic Increasing the synthesis and release of dopamine (L-dopa+karbidopa dopa+karbidopa, amantadin) Inhibiting dopamin metabolism (selegilin/deprenil) Activating dopamine receptor (bromocriptine( bromocriptine, pergolide) Blocking muscarinic/ cholinergic receptor (trihexiphenidile, benzathropine, diphenhidramine)

Protocol of therapy Anti cholinergic Amantadine L-dopa+karbidopa Dopamine agonists drugs MAO B inhibitors

L-dova (levodopa) Dopamine precursor inactive form Activated by decarboxilase enzyme; Brain Lever & kidneys can not pass through BBB bioavailability countered by karbidopa/benserazide. Interaction: piridoxine increases decarboxilated reaction. On/off phenomenon (+) after 3-53 5 years application mechanism??? Desensitization of dopamine receptor Not a first line therapy

Selegiline (deprenil) Instead of inhibiting metabolism of dopamine: Stimulating dopamine release. Neuro-protective effect + MOA inhibitors crisis of hypertension. Bromociptine & Pergolide Dopamine receptor agonists Action: Lesser than L-dopaL As a single therapy at the early stage Combination with L-dopa L dopa at the moderate and late stage. Tapering dose

Trihexiphenidile & benzotropine Action: less than L-L dopa Adjuvant therapy Tapering dose Diphenhidramine Anti cholinergic effect at central level Anti histamine

Amantadine Anti virus Mechanism:??? May be by facilitating dopamine release Action: Less than L-dopaL Better than anti cholinergic Early stage: Anti cholinergic or Amantadine When early stage therapy is not effective, L-L dopa+karbidopa are started. Final stage: dopamine agonists medications and MAO inhibitors.

Headache/Cephalgia Migraine Tension headache Cluster headache

Migraine Mechanism: Genetic Vascular Neural Neurotransmitter serotonin Neurotransmitter dopamine Activation of symphatic nervous system NSAIDs + caffeine (asetaminophen,, acetic salicilic acid, etc) Serotonin receptor agonists (ergotamine, dihidroergotamine, sumatriptane, naratriptane, rizatriptane, zolmatriptane) Dopamine antagonist (metochlopramide,, CPZ, procpz)

Protocol of therapy Mild migraine NSAIDs, or Serotonin receptor agonist (oral) Moderate migraine Serotonin receptor agonists (oral/nasal/sc), or Dopamine receptor antagonist (oral) Heavy migraine Serotonin receptor agonists (SC/IM/IV), or Dopamine receptor antagonist (IM/IV)

NSAIDs SE: dispepsia Stimulator of serotonin (5-HT HT1) ) receptors: 1. ergotamine, dihidroergotamine Non selective 5-HT5 HT1 receptor agonist Contra indication: CHD, pregnancy, peripheral blood vessel constriction, level and kidney disorders.

2. triptan Selective 5-HT5 HT1 receptor agonist Rizatriptan: : quickest onset, highest efficacy Naratriptan: : in contrast Monotherapy is unadvisable Contra indication: cardiovascular diseases

Dopamine antagonists Adjuvant therapy Increasing gut motility Also could treat: Nausea & vomit Prevention 3 times per month Beta blockers (propanolol( propanolol, timolol) Anti convulsive agents (valproic acid) MAO inhibitors (phenelzine, isokarbosazide) Serotonergic agents (metisergide, siproheptadine) Ca antagonist (verapamil( verapamil)

Tension headache Usually bilateral Usually following anxiety or depression Therapy: NSAIDs + coffeine Muscle relaxant agents Prevention: amitriptiline a.n

Cluster headache Periorbital pain (temporal bone pain) Some signs and symptoms related to eyes Mechanism:??? May be serotonergic transmission disorder Therapy: Prednison Lithium Metisergid Ergotamine Na valproic Verapamil